InterVenn

05/28/2026

Precision medicine is evolving — and women’s health deserves to be at the center of that evolution.

At InterVenn, we are mapping glycoprotein signals that may provide deeper understanding of disease biology and support more personalized clinical insight.

We believe the future of diagnostics is not just detecting disease — but understanding how disease behaves in real time.

Follow InterVenn for updates on women’s health innovation.

05/26/2026

Women facing ovarian cancer concerns deserve clearer answers and greater confidence in care decisions.

InterVenn’s GlycoKnow™ Ovarian is designed to help assess malignancy risk in women with pelvic masses using a blood-based glycoproteomics-powered approach.

Our mission is simple: to provide better insight, reduce uncertainty, and advance precision medicine in women’s health.

GlycoKnow™ Ovarian is intended for use by healthcare professionals as an adjunct to existing clinical assessment tools. For more information on intended use and performance, please visit our website. The test has not been evaluated or approved by the US FDA.

05/21/2026

What is glycoproteomics — and why does it matter in women’s health?

Proteins carry glycans, complex sugar structures that influence how diseases develop and progress. By analyzing these glycan signatures, glycoproteomics provides deeper biological insight than genomics or traditional proteomics alone.

At InterVenn, we believe these signals may unlock a powerful new approach to earlier, more confident clinical insight in women’s health.

Visit InterVenn.com to learn more about glycoproteomics.

05/19/2026

Women’s Health Month is a reminder that every woman deserves access to earlier answers, deeper insight, and more confident care. At InterVenn, we believe the future of women’s health diagnostics lies beyond traditional approaches — unlocking the biological signals hidden within glycoproteomics.

We are proud to advance precision medicine solutions designed to support clinicians and improve patient journeys in ovarian cancer risk assessment and beyond.

Together, we can help shape a new frontier in women’s health.

Learn more about GlycoKnow™ Ovarian and InterVenn’s work in women’s health diagnostics: https://intervenn.com/glycoknow

05/18/2026

We’re excited to welcome Alec Ford and Mitch Levine to the InterVenn Biosciences Board of Directors!

Their extensive leadership experience across diagnostics, biotechnology, commercialization, and finance will help guide InterVenn through our next phase of growth as we advance glycoproteomics and precision medicine.

At InterVenn, we believe the glycoproteome holds critical biological insights that can transform how diseases are detected and managed — helping create a future where patient care is more personalized and effective.

Welcome to the team, Alec and Mitch!

Read the full press release here: https://www.prnewswire.com/news-releases/intervenn-appoints-industry-leaders-alec-ford-and-mitch-levine-to-board-of-directors-302774032.html

05/09/2026

Every woman deserves answers sooner.

On World Ovarian Cancer Day, we recognize the urgent need for better tools to help assess ovarian cancer risk earlier and more accurately.

At InterVenn Biosciences, we are advancing a new frontier in precision medicine through glycoproteomics — unlocking biological signals traditional approaches cannot see.

Our GlycoKnow™ Ovarian test is designed to help distinguish malignant from benign pelvic masses using a simple blood sample, supporting more informed clinical decision-making for women facing uncertainty.

Women’s health deserves innovation.
Clinicians deserve better insights.
Patients deserve clarity sooner.

Together, we can help transform the future of ovarian cancer care.

05/07/2026

Please join us in welcoming David King, Chief Operating Officer, and Nick Khadder, Chief Legal and Administrative Officer, to the InterVenn family!

We are excited that they have joined us as we continue advancing a new frontier in precision medicine through the power of glycoproteomics.

Their expertise and leadership will help support our mission to develop transformational healthcare solutions and improve patient outcomes through deeper biological insight.

Welcome to the team, David and Nick — exciting things ahead!

05/04/2026

ACOG was just the beginning.

Thank you to everyone who stopped by the InterVenn booth to learn more about GlycoKnow™ Ovarian and our emerging work to advance endometriosis diagnostics.

Today, too many women face medical uncertainty—unnecessary surgery, delayed diagnosis, or unclear next steps. We’re working to change that.

GlycoKnow™ Ovarian is a blood-based test designed to help assess malignancy risk in women with pelvic masses—supporting more confident, informed clinical decisions.

And we’re building what’s next: a non-invasive approach to help identify endometriosis earlier, with the potential to avoid years of diagnostic delay.

👉 Learn more: https://intervenn.com/
👉 Schedule time with our team: https://intervenn.com/

Join us to help improve clarity in women’s health clinical decision-making.



GlycoKnow™ Ovarian is intended for use by healthcare professionals as an adjunct to existing clinical assessment tools. For more information on intended use and performance, please visit our website.

05/02/2026

ACOG is in full swing.

What’s the biggest unmet need in women’s health diagnostics?

We want to hear from you.

Visit us at Booth 1546 and share your perspective.

Complete our survey for a chance to win an iPad.

Let’s shape the future—together.

03/09/2023

In celebration of Women’s History Month, we honor all women who make invaluable contributions across the world. And today we are thrilled to share how one of our own, Ada Wong, has been recognized by BioPharma APAC as a one of the Leading Women in Life Science and Biotech. Congrats, Ada!

Meet Leading Women in the Life Science and Biotech Industry